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Key Points: 
Hypoxaemia is defined as a lower than normal arterial blood oxygen level, whilst hypoxia refers to a 
lack of oxygen at a cellular level.  
Hypoxaemia is a common presentation in critically ill patients, with the potential for severe harm if 
not addressed early.  
Determining the nature, cause and severity of hypoxaemia is a key step in enabling effective 
treatment.  
The treatment strategies required will be dependent on the clinical picture and may involve a 
combination of non-invasive and invasive modalities.  
Severely hypoxaemic patients, not responding to initial treatment, should be discussed with critical 
care and specialist respiratory teams early.  
Whilst some specialist centres may use advanced treatment strategies such as extra-corporeal 
membranous oxygenation (ECMO) in this patient group, further research to support and quantify 
their effectiveness is still required. 
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Abstract: 
Hypoxaemia is a common presentation in critically ill patients, with the potential for severe 
harm if not addressed appropriately. The aim of this review is to provide a framework to 
guide the management of any hypoxaemic patient, regardless of the clinical setting. Key 
steps in managing such patients include ascertaining the severity of hypoxaemia, the 
underlying diagnosis and implementing the most appropriate treatment. Oxygen therapy 
can be delivered by variable and fixed rate devices, and non-invasive ventilation; if patients 
deteriorate they may require tracheal intubation and mechanical ventilation. Early critical 
care team involvement is a key part of this pathway. Specialist treatments for severe 
hypoxaemia can only be undertaken on an intensive care unit and this field is developing 
rapidly with the trial results becoming available. It is important that each new scenario is 
approached in a structured manner yet with an open diagnostic mind and a clear escalation 
plan. 
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Introduction 
Hypoxaemia refers to a lower than normal arterial blood oxygen level, measured either as oxygen 
saturation (SaO2) or partial pressure of oxygen (PaO2). It is a common feature of acutely unwell 
hospitalised patients and can result in substantial morbidity and mortality if not treated rapidly and 
appropriately. Hypoxaemic patients may require admission to an intensive care unit (ICU), with more 
than 60% of those that do eventually requiring invasive ventilation. The mortality of hypoxaemic 
critically ill patients is 27%, rising to as high as 50% in patients with severe hypoxaemia (Grimaldi 
2018). 
A structured approach to the management of hypoxaemic patients is essential in order to establish a 
diagnosis and implement the most appropriate therapy. Knowledge of relevant physiology is 
important when considering both the diagnosis and treatment. Tailoring therapies to individual 
patients will be necessary, particularly in terms of oxygenation targets  
The aim of this review is to provide a logical framework that can facilitate the management of all 
hypoxaemic patients. The evidence base in this field is in a constant state of flux and there have 
been a number of key publications in the past few years that have made us rethink our approach to 
this problem.  
Definitions and basic physiology  
Hypoxaemia 
No specific threshold of SaO2 or PaO2 defines hypoxaemia. Suggested normal values for PaO2 are 
10.5 – 13.5 kPa, and for SpO2 are 94-98% (O’Driscoll 2017). This information can be obtained via 
arterial blood gas (providing PaO2 and SaO2) and pulse oximetry (providing SpO2). It should be noted 
4 
Management of hypoxaemia in the critically ill patient   
that normal values decline with age and are influenced by the presence of co-morbidities such as 
chronic lung disease.  
Describing the magnitude of hypoxaemia in a patient receiving oxygen can be challenging; from a 
physiological perspective, knowledge of the alveolar-arterial partial pressure difference (PA-aO2) or 
‘Aa gradient’ can be useful when determining the cause of hypoxaemia. It requires the patient’s 
arterial partial pressure of carbon dioxide (PaCO2) to calculate it. Alternatively, the PaO2 to fraction 
of inspired oxygen (FIO2) ratio (PF ratio) may be a helpful guide to quantifying the degree of 
hypoxaemia and is frequently used in the setting of an ICU (see table 1).  
Hypoxaemia may result from a multitude of pathologies; however, the basic physiology underlying 
these can be split into: hypoventilation, ventilation-perfusion (VQ) mismatch (either an increased or 
decreased VQ ratio), right to left circulatory shunting of blood, impaired diffusion of oxygen across 
the alveolar membrane and a reduced FIO2 (Sarkar 2017). Respiratory failure is a broad term that 
describes inadequate gas exchange that either consists of hypoxaemia alone (type 1) or in 
combination with hypercapnia (type 2).  
Hypoxia 
The term hypoxia generally refers to a lack of oxygen at a cellular level. Severe hypoxia can affect the 
production of ATP by mitochondrial oxidative phosphorylation, threatening cellular integrity. Non-
oxygen dependent bioenergetic pathways are referred to as anaerobic metabolism; they are short-
term inefficient systems that are unable to sustain life for prolonged periods of time in humans. A 
brief summary of the causes of hypoxia can be seen in table 2. 
One of the challenges in critically ill patients is that cellular oxygen levels cannot be measured. 
Anaerobic metabolism produces lactate as a biproduct; however, this generally indicates poor organ 
perfusion (ischaemic hypoxia) rather than a lack of oxygen.  
Acute Respiratory Distress Syndrome (ARDS) 
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ARDS is defined as: “The presence of new or worsening respiratory symptoms within 1 week of 
onset of symptoms; bilateral opacities on chest imaging not fully explained by effusions, atelectasis 
or nodules; respiratory failure from lung oedema not fully explained by cardiac failure or fluid 
overload; and oxygenation impairment. The degree of oxygenation impairment is defined by the 
following PF ratios: mild 40.0–26.8 kPa; moderate 26.7–13.4 kPa; severe ≤13.3 kPa.” (ARDS definition 
task force 2012).  
ARDS can present in a broad range of patients and have a multitude of causes. The incidence in UK 
ICUs was estimated to be 12.5% (Summers 2016) and data from a worldwide multi-centre study 
suggested an in-hospital mortality of up to 40% (Bellani 2016). The pathophysiology that underlies 
ARDS is likely secondary to acute lung inflammation, resulting in increased vascular permeability, 
pulmonary oedema and worsening surfactant function. The culmination of this results in worsening 
gas exchange, shunt formation and worsening V/Q mismatch (Pham 2017). When severe this leads 
to extreme hypoxaemia.  The complex pathophysiology behind ARDS means multiple treatment 
strategies have been suggested and trialled, often with little effect on mortality.  
 
Initial approach to the hypoxaemic patient 
Clinical Assessment 
As with any acutely unwell patient, it is important to adopt the Airway, Breathing, Circulation, 
Disability, Exposure (ABCDE) approach to assessment and management. During this it is essential to 
look for any life-threatening causes of hypoxaemia (e.g. pneumothorax) so these can be treated 
swiftly. The degree of hypoxaemia and nature of respiratory failure should be determined early, and 
appropriate monitoring implemented to evaluate deterioration and effectiveness of treatment. On 
ICU this usually consists of continuous SpO2, intermittent ABGs and careful documentation of FIO2. It 
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is also important to ascertain any past medical history suggestive of chronic cardiopulmonary 
disease as this will aid in differentiating between worsening of chronic disease or acute pathology. 
 
Investigations 
It is important to try and identify the underlying cause of hypoxaemia so that an appropriate 
treatment may be initiated. Table 3 summaries the common causes of hypoxaemia by pathology. A 
routine panel of blood tests is indicated in most cases, with more specific tests (e.g. d-dimer and 
cardiac enzymes) to be performed as clinically indicated. If infection is suspected then blood 
cultures, an atypical pneumonia screen, sputum samples and HIV tests may also be relevant. 
Depending on the clinical presentation it may also be appropriate to consider diagnoses such as 
mycobacterium tuberculosis, pneumocystis pneumonia and vasculitis. Intubated patients may 
benefit from a bronchoscopy +/- bronchoalveolar lavage, as this can be both a beneficial diagnostic 
and therapeutic tool. 
 
Imaging 
Chest X-rays and ultrasound scans can be performed quickly and easily at the bedside and maintain a 
high level of sensitivity and specificity across a broad range of pathologies. More complex cases may 
require cross-sectional imaging in the form of computerised-tomography +/- pulmonary 
angiography. Echocardiography is also a useful and quick bedside diagnostic tool; particular 
attention should be paid to right ventricular function and pulmonary artery pressure, as this may aid 
diagnosis of acute or chronic pathologies (e.g. pulmonary emboli or pulmonary hypertension) and 
help guide treatments thereafter. 
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Non-invasive treatment strategies 
Some general strategies can be used when approaching almost all ward-based hypoxaemic patients. 
It is important all such patients are managed in high-acuity wards, with constant pulse oximetry, 
regular clinical reviews and if appropriate, blood gas analysis.  
 
Management of Type 1 Respiratory Failure 
This is defined as hypoxaemia without hypercapnia. Firstly, simple strategies such as optimising 
patient positioning by sitting them upright, physiotherapy and upper airway suctioning in patients 
with abundant or thick secretions may aid ventilation. Variable performance oxygen masks and nasal 
cannula may be appropriate initially; however, their design prevents accurate or high concentration 
oxygen delivery. Patients with severe hypoxaemia may require high-flow oxygen, delivered via fixed 
performance masks with a precise FIO2. Venturi masks fit these criteria and are available for 24 to 
60% oxygen. Anaesthetic breathing systems such as the Water’s circuit also use high-flow oxygen 
and can deliver up to 100% oxygen. A non-rebreathe mask requires 15 l/min of oxygen and can 
deliver up to 80% oxygen. 
If traditional oxygen delivery systems fail to adequately oxygenate a patient, continuous positive 
airway pressure (CPAP) ventilation may be beneficial (BTS 2012). CPAP improves oxygenation by 
preventing the collapse of alveoli and small airways at the end of expiration and lessening VQ 
inequality via redistribution of fluid within the lungs (Mas 2014). Low levels of end-expiratory 
pressure can also improve cardiac function in the presence of left ventricular failure (by reducing the 
afterload) or right ventricular failure (by reducing the preload) (Sin 2000, Agarwal 2005). 
Administering CPAP requires specialist skills and frequent patient observations and review.  
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An alternative is high-flow nasal oxygen (HFNO), which provides flow rates of up to 60 litres per 
minute and delivers precise humidified oxygen concentrations up to 100%. It has been associated 
with significant improvement in acutely hypoxaemic patients in ICU (Sztrymf 2012). Proposed 
mechanisms of action include: positive airway pressure generation, flushing of dead space gas and 
benefits from humidification and heating of the oxygen delivered through the circuit (Ashraf-Kashani 
2017). 
 
Management of Type 2 Respiratory Failure 
Type 2 respiratory failure is hypoxaemia with associated hypercapnia and is common in patients with 
chronic obstructive airways disease (COPD). The approach to managing a patient with hypercapnic 
respiratory failure (T2RF) is similar to T1RF, with the avoidance of severe hypoxaemia remaining key.  
The first step in treating these patients is the initiation of oxygen via a fixed performance device. A 
sub-group of patients with COPD are at increased risk of T2RF due to a combination of worsening VQ 
mismatch (following the loss of hypoxic pulmonary vasoconstriction), the Haldane effect and 
decreased minute ventilation (Hanson 1996). In such patients supplemental oxygen must be 
carefully titrated using fixed performance, with acid / base balance, neurological status and carbon 
dioxide levels closely monitored. It is important to emphasise that the risk of severe hypoxaemia in 
these patients outweighs that of hypercapnia.   
If hypoxaemia and / or hypercapnia persists, non-invasive ventilation should be considered. Bi-level 
positive airway pressure (BIPAP) is the appropriate intervention; its benefit over CPAP for these 
patients is the addition of an inspiratory pressure to augment their tidal volume. The rise in minute 
ventilation that results from this should reduce PaCO₂. It is important these patients are reviewed 
regularly and their BIPAP settings adjusted according to their response. The British Thoracic Society / 
Intensive Care Society joint guidelines currently advise starting at an inspiratory pressure of 15 
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cmH2O and positive end expiratory pressure (PEEP) of 3 cmH2O, with the view to up titrate over 10-
30 minutes until adequate ventilation is reached (targeting an SpO2 of 88-92%). If inspiratory 
pressure reaches >30 cmH2O or PEEP >8 cmH2O then expert review is advised. Contraindications to 
BIPAP include airway obstruction, recent upper gastrointestinal or cranio-facial surgery, facial / 
airway burns, high risk of aspiration and untreated pneumothoraces (Davidson 2015).  
 
Management of mechanically ventilated patients 
Failure to respond to high-flow oxygen and / or NIV may require a patient to be transferred to an ICU 
for consideration for invasive ventilation. Early referral to the ICU team will help them to assess the 
situation and determine the need for transfer. Indications for intubation and critical care referral for 
hypoxaemic patients include an inability to: maintain their airway; protect their airway from 
aspiration (e.g. low GCS); ventilate sufficiently; oxygenate sufficiently despite optimisation of non-
invasive techniques; or anticipation of a deteriorating clinical picture. Mechanical ventilation in the 
acutely unwell patient requires sedation and usually neuromuscular blockade to facilitate tracheal 
intubation.  
Not all patients will be suitable for this level of treatment as it comes at risk of multiple organ failure 
and prolonged ventilation and the possibility of the need for a tracheostomy. The ICU team, in 
discussion with the primary team, patient and patient’s relatives should establish this as soon as 
possible. Whilst mechanical ventilation should improve oxygenation and CO2 clearance, it will not 
treat the underlying pathology; this will also need to be addressed to promote recovery.  
A number of strategies have been used in mechanically ventilated ICU patients with respiratory 
failure, around 1/3 of whom will not survive (ICNARC 2018). Much of the research to date has 
focused on patients with ARDS but strategies for this syndrome can be considered in all patients 
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with refractory hypoxaemia. What follows is a synopsis of these treatment strategies with the 
evidence base supporting their use.  
 
Pharmaceutical approaches 
Over recent years various pharmacological strategies have been trialled to aid management in 
severely hypoxaemic patients.  
1. Neuro-muscular blocking agents (NMBA) are used to improve synchronisation of ventilation 
between the patient and ventilator, thus hopefully improving oxygenation and carbon 
dioxide clearance. A reduced mortality and number of days requiring mechanical ventilation 
has been demonstrated when used in patients with moderate to severe ARDS (Papazian 
2010). Current consensus is in favour of their use in patients suffering from moderate or 
severe ARDS (Griffiths 2019). 
2. Corticosteroids may be indicated for specific underlying diagnoses such asthma or COPD, 
usually in fairly modest doses. In patients suffering from ARDS, high-dose steroid strategies 
(e.g. 1 g IV methylprednisolone), have a low level of evidence supporting their use, with a 
possible associated reduction in mortality (Lamontagne 2009). However, the overall 
evidence pool remains largely equivocal. 
3. Inhaled vasodilators (such as epoprostenol and nitric oxide) have also been used, this is 
based on the theory that they promote selective vascular dilatation in well ventilated areas 
of the lung, lessening VQ inequality (see fig 1). To date, no mortality benefit has been shown 
with their use (Griffiths 2019). However, some suggestions have been made supporting their 
use as a bridging strategy prior to rescue therapies such as extra-corporeal membranous 
oxygenation (Wright 2015). 
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Fluid Management 
Fluid management in hypoxaemic patients is often complex and dependant on the underlying 
aetiology of the hypoxaemia. The overwhelming opinion is to avoid excess positive fluid balance. 
This is particularly relevant in cardiogenic pulmonary oedema and ARDS. Trials have demonstrated a 
decreased mortality associated with a conservative (neutral) vs liberal fluid approach in such 
patients and therefore this approach is currently advised (NHLBI ARDS Clinical Trials Network 2006, 
Griffiths 2019).   
 
Ventilation strategies 
All mechanically ventilated patients should receive lung protective ventilation. This has been defined 
as a tidal volume (TV) of ≤ 6 ml/kg and plateau pressure ≤ 30 cmH2O (as per ARDSnet protocol). This 
has been shown to reduce mortality, and local and systemic inflammation in mechanically ventilated 
patients (ARDSnet 2000, Wolthuis 2008). Originally recommended for those patients with ARDS, it is 
now clear that to prevent damage to lung parenchyma lung protective ventilation should be the 
default whenever mechanical ventilation is required. Thus, the consensus is that most patients 
should be ventilated with a TV of ≤ 6 ml/kg, unless there is a specific contraindication. 
The use of high PEEP (> 10 cmH2O) in hypoxaemic patients stems from the idea that it may improve 
alveolar ventilation by reducing atelectasis and splinting small airways open. Trials looking into the 
use of high PEEP in patients with ARDS demonstrated that patients who improved following its 
initiation, then benefitted from its continued use, with no increase in hyper-inflation and 
barotrauma recorded (Guo 2018). Evidence to date is in support of the use of high PEEP in patients 
with severe hypoxaemia/ARDS who are initially responsive to high PEEP levels (Griffiths 2019). A 
degree of PEEP, although not high, is used in the majority of ventilated patients. 
Prone positioning 
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In patients with moderate or severe ARDS a strong evidence base is forming regarding the benefits 
of ventilating them in the prone position. The prone position improves VQ matching by creating a 
more homogenous pleural pressure gradient, reducing atelectasis and improving drainage of 
secretions (see Fig. 2).  Meta-analyses have shown a reduction in mortality in patients suffering from 
ARDS, most significantly so when patients are in the prone position for at least 12 hours (Hu 2014, 
Park 2015).  
 
Extra-corporeal CO2 removal (ECCOR): 
The CO₂ removal provided by this technique allows lung protective and ultra-low TV to be used in 
acutely hypoxaemic patients, who would otherwise develop severe hypercapnic acidosis 
(Peperstraete 2017). There is currently ongoing research being performed looking into use of ECCOR 
in awake patients suffering from COPD in order to prevent intubation. At this time there is no 
evidence for or against this treatment strategy so further research is required. Other suggested 
management strategies include permissive hypercapnia, permissive acidosis (pH >7.2) and the use of 
sodium bicarbonate, however, more research is required.  
 
Extra-corporeal membranous oxygenation (ECMO)  
A full description of ECMO is beyond the scope of this article. Veno-venous ECMO facilitates 
oxygenation of severely hypoxaemic patients via an extracorporeal circuit and is only available in 
specialist centres. It requires the insertion of large cannulae into central vessels, anticoagulation of 
the circulation and specialist ICU nursing skills. In patients with severe refractory hypoxaemia, 
referral to a specialist ECMO should be considered early. Criteria for referral to such centres may 
vary but are generally: severe hypoxaemia (PF ratio <13.3 kPa), severe hypercapnic acidosis (pH 
<7.20), inability to achieve lung protective tidal volumes, nil improvement with rescue therapies 
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such as prone position and significant air leak or broncho / pleural fistula. The evidence surrounding 
the use of ECMO in patients with ARDS is constantly being re-visited, with a small reduction in 
mortality suggested historically (Peek 2009). However, the 2018 EOLIA trial looking at ECMO in 
severe ARDS showed no significant improvement in 60 day mortality, with the trial terminated early 
for futility (Combes 2018).  
 
Conclusion 
Management of a critically ill hypoxaemic patient can be a complex and challenging task. It is 
important to maintain a structured approach, attempt to identify an underlying cause and pay close 
attention to any signs of deterioration. The degree and nature of hypoxaemia will direct the chosen 
treatment route. The clinical picture should constantly be re-reviewed, whilst asking one’s self: Is 
this patient still severely hypoxaemic? Does this patient require escalation to critical care? Does this 
patient require referral to a tertiary respiratory centre? If the answer to any of these questions is 
yes, then immediate advice should be sought. In patients requiring invasive ventilation, lung 
protective techniques should be used in all cases. Treatment strategies such as the prone position, 
high PEEP, corticosteroid use, NMBA and a conservative fluid balance may be beneficial in patients 
with moderate to severe ARDS. Whilst ECMO, ECCOR and inhaled vasodilators may also confer some 
benefit, more research is indicated to support their ongoing use. 
The treatment of severe hypoxaemia is likely to continue to evolve as more research and trials are 
performed. Nevertheless, as clinicians it is important we approach each new scenario with a reliable 














Healthy alveoli Diseased alveoli 
Vasodilator 
Figure 1. Poorly aerated regions of lung result in VQ mismatch, as blood to these areas is poorly 
oxygenated. Inhaled vasodilators result in dilatation of vasculature surrounding healthy lung units, 
with increased blood flow, oxygenation and thus reduction in V/Q mismatch and shunting. 
Vasodilatation of 
pulmonary blood flow 
to healthy alveoli 
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Figure 2. When supine, gravity and the weight of the heart result in compression of dependant dorsal areas 
of lung and thus hypoventilation. In the prone position, the alveoli become more homogenous and the 
weight of the heart is instead on the sternum. This leads to increased perfusion of dorsal lung segments with 
reduced V/Q mismatch. Perfusion in the lung is remains largely dorsal in both the supine and prone position. 
Note red shading indicates most perfused lung regions. 
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Tables 
Table 1. PaO2 to FiO2 ratio association with severity of hypoxaemia. 
0.21 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00
4.0 19.0 16.0 13.3 11.4 10.0 8.9 8.0 7.3 6.7 6.2 5.7 5.3 5.0 4.7 4.4 4.2 4.0
4.5 21.4 18.0 15.0 12.9 11.3 10.0 9.0 8.2 7.5 6.9 6.4 6.0 5.6 5.3 5.0 4.7 4.5
5.0 23.8 20.0 16.7 14.3 12.5 11.1 10.0 9.1 8.3 7.7 7.1 6.7 6.3 5.9 5.6 5.3 5.0
5.5 26.2 22.0 18.3 15.7 13.8 12.2 11.0 10.0 9.2 8.5 7.9 7.3 6.9 6.5 6.1 5.8 5.5
6.0 28.6 24.0 20.0 17.1 15.0 13.3 12.0 10.9 10.0 9.2 8.6 8.0 7.5 7.1 6.7 6.3 6.0
6.5 31.0 26.0 21.7 18.6 16.3 14.4 13.0 11.8 10.8 10.0 9.3 8.7 8.1 7.6 7.2 6.8 6.5
7.0 33.3 28.0 23.3 20.0 17.5 15.6 14.0 12.7 11.7 10.8 10.0 9.3 8.8 8.2 7.8 7.4 7.0
7.5 35.7 30.0 25.0 21.4 18.8 16.7 15.0 13.6 12.5 11.5 10.7 10.0 9.4 8.8 8.3 7.9 7.5
8.0 38.1 32.0 26.7 22.9 20.0 17.8 16.0 14.5 13.3 12.3 11.4 10.7 10.0 9.4 8.9 8.4 8.0
8.5 40.5 34.0 28.3 24.3 21.3 18.9 17.0 15.5 14.2 13.1 12.1 11.3 10.6 10.0 9.4 8.9 8.5
9.0 42.9 36.0 30.0 25.7 22.5 20.0 18.0 16.4 15.0 13.8 12.9 12.0 11.3 10.6 10.0 9.5 9.0
9.5 45.2 38.0 31.7 27.1 23.8 21.1 19.0 17.3 15.8 14.6 13.6 12.7 11.9 11.2 10.6 10.0 9.5
10.0 47.6 40.0 33.3 28.6 25.0 22.2 20.0 18.2 16.7 15.4 14.3 13.3 12.5 11.8 11.1 10.5 10.0
10.5 50.0 42.0 35.0 30.0 26.3 23.3 21.0 19.1 17.5 16.2 15.0 14.0 13.1 12.4 11.7 11.1 10.5
11.0 52.4 44.0 36.7 31.4 27.5 24.4 22.0 20.0 18.3 16.9 15.7 14.7 13.8 12.9 12.2 11.6 11.0
11.5 54.8 46.0 38.3 32.9 28.8 25.6 23.0 20.9 19.2 17.7 16.4 15.3 14.4 13.5 12.8 12.1 11.5
12.0 57.1 48.0 40.0 34.3 30.0 26.7 24.0 21.8 20.0 18.5 17.1 16.0 15.0 14.1 13.3 12.6 12.0
12.5 59.5 50.0 41.7 35.7 31.3 27.8 25.0 22.7 20.8 19.2 17.9 16.7 15.6 14.7 13.9 13.2 12.5
13.0 61.9 52.0 43.3 37.1 32.5 28.9 26.0 23.6 21.7 20.0 18.6 17.3 16.3 15.3 14.4 13.7 13.0
13.5 64.3 54.0 45.0 38.6 33.8 30.0 27.0 24.5 22.5 20.8 19.3 18.0 16.9 15.9 15.0 14.2 13.5
14.0 66.7 56.0 46.7 40.0 35.0 31.1 28.0 25.5 23.3 21.5 20.0 18.7 17.5 16.5 15.6 14.7 14.0
14.5 69.0 58.0 48.3 41.4 36.3 32.2 29.0 26.4 24.2 22.3 20.7 19.3 18.1 17.1 16.1 15.3 14.5
15.0 71.4 60.0 50.0 42.9 37.5 33.3 30.0 27.3 25.0 23.1 21.4 20.0 18.8 17.6 16.7 15.8 15.0
SEVERITY OF HYPOXAEMIA
According to P:F Ratio
Nil
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Cause of Hypoxia PaO2 Common causes Treatment strategies 
Hypoxic Low Altitude Supplementary oxygen  
Anaemic Normal Bleeding and anaemia Blood transfusion and address 
underlying cause of anaemia 
[increasingFIO2 is not beneficial] 
Ischaemic Normal Embolism, thrombus Treat underlying cause by 
increasing blood flow to target 
organ [increasingFIO2 is not 
beneficial] 
Histotoxic Normal Cyanide poisoning Reverse / address causal agent, 
[increasingFIO2 is not beneficial] 
 
Table 2. Causes of hypoxia (a lack of oxygen at the cellular level) 
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Table 3. Common causes of hypoxaemia 
Pathology 
 
Speed of onset and 
symptoms 
Examination findings Diagnosis Treatment 
Pneumonia Days to weeks, infective 
symptoms, check travel 
Hx 
Pleuritic chest pain, 
systemic signs of infection, 
possible crackles/bronchial 
breathing on auscultation 
CXR, sputum 
samples, CT may be 
required if complex 
As per local sepsis and anti-
microbial guidelines, 
supplementary oxygen often 
required 
Pulmonary oedema Acute if new event. If 
inpatient, check fluid 
balance and preceding 
history 
Peripheral signs of heart 
failure if cardiogenic, bi-




If acute event – as per ACS 
treatment, diuresis, CPAP to 
be considered 
Pneumothorax Commonly acute Pleuritic chest pain, 
reduced air entry, 
increased resonance on 
percussion 
CXR, ultrasound 
scan, CT may be 
required if complex 
If tension Px – needle 
decompression and chest 
drain insertion, otherwise as 
per BTS guidelines dependant 
on size and PMH 
Pulmonary 
embolism 
Commonly acute, can 
present as chronic – Hx 
often reduced mobility or 
pro-coagulant state 




CTPA as gold 
standard, ECHO for 
R heart strain, V/Q 
scan if CTPA not 
possible 
If circulatory collapse and nil 
contra-indications – 
thrombolysis as per 
guidelines. Otherwise anti-
coagulation as per BTS 
Pleural effusion Acute or chronic Reduced air entry at site of 
effusion, stony dull to 
percuss 
CXR, ultrasound, CT 
scan is complex 
As per BTS management, if 
significant or possibly 
infective then pleural tap +/- 
drain insertion 
Haemothorax Commonly acute, often 
associated with trauma 
Reduced air entry, dull to 
percuss, may have signs of 
trauma 
CXR, ultrasound, CT 
scan 
If indicated – surgical chest 
drain insertion 
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